


## Eupatilin

Cat. No.:	HY-N0783
CAS No.:	22368-21-4
Molecular Formula:	C <sub>18</sub> H <sub>16</sub> O <sub>7</sub>
Molecular Weight:	344.32
Target:	PPAR; Autophagy
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor; Autophagy
Storage:	Powder    -20°C    3 years 4°C    2 years In solvent   -80°C    2 years -20°C    1 year



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 33.33 mg/mL (96.80 mM; Need ultrasonic)				
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div> <div>Mass</div>	1 mg	5 mg	10 mg
		1 mM	2.9043 mL	14.5214 mL	29.0428 mL
		5 mM	0.5809 mL	2.9043 mL	5.8085 mL
		10 mM	0.2904 mL	1.4521 mL	2.9043 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil				
	Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	Eupatilin, a lipophilic flavonoid isolated from <i>Artemisia argyi</i> Lévl. et Van., is a <i>PPARα</i> agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.
IC <sub>50</sub> & Target	PPARα
In Vitro	Eupatilin is a <i>PPARα</i> agonist. Eupatilin (10, 30, 100 μM) suppresses IL-4 expression and degranulation in RBL-2H3 cells <sup>[1]</sup> .

	<p>Eupatilin (50-100 <math>\mu</math>M) slightly reduces cell viability of HaCaT cells. Eupatilin (10, 30, 50, 100 <math>\mu</math>M) increases PPAR<math>\alpha</math> transactivation and expression in HaCaT cells. Eupatilin (10, 30, 50 <math>\mu</math>M) also suppresses TNF<math>\alpha</math>-induced MMP-2/-9 expression in HaCaT cells. Furthermore, Eupatilin inhibits TNF<math>\alpha</math>-induced p65 translocation, I<math>\kappa</math>B<math>\alpha</math> Phosphorylation, AP-1 and MAPK signaling via PPAR<math>\alpha</math><sup>[2]</sup>. Eupatilin (10-50 <math>\mu</math>M) shows no cytotoxic effects on ARPE19 cells. Eupatilin (10, 25, 50 <math>\mu</math>M) elevates cell viability from oxidative stress, and inhibits H<sub>2</sub>O<sub>2</sub>-induced ROS production in ARPE19 cells. Moreover, Eupatilin (50 <math>\mu</math>M) inhibits H<sub>2</sub>O<sub>2</sub>-induced cells apoptosis and promotes the activation of PI3K/Akt pathway in RPE cells<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>In Vivo</b>	<p>Eupatilin (1.5% or 3.0%) restores PPAR<math>\alpha</math> mRNA expression, and improves atopic dermatitis (AD)-like symptoms in oxazolone-induced Balb/c mice. Eupatilin causes significant decrease in serum IgE, IL-4 levels, oxazolone-induced TNF<math>\alpha</math>, IFN <math>\gamma</math>, IL-1<math>\beta</math>, TSLP, IL-33 and IL-25 mRNA expression in oxazolone-induced mice. Eupatilin also increases filaggrin and loricrin mRNA expression in oxazolone-induced mice<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## PROTOCOL

<b>Cell Assay</b> <sup>[3]</sup>	<p>Cell viability is detected using a MTT assay. In brief, after treatment, the medium is replaced with fresh medium containing 0.5 mg/mL MTT for 4 h at 37°C. Then, the medium is gently aspirated and 150 <math>\mu</math>L of DMSO is added to each well to solubilize the formazan crystals. The absorbance is measured at 450 nm by a microplate reader. The relative cell viability is defined as the absorbance of treated wells divided by that of the control<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>Animal Administration</b> <sup>[1]</sup>	<p>Six-week-old female Balb/c mice are housed under conditions of controlled temperature (23 <math>\pm</math> 2°C), humidity (55 <math>\pm</math> 5%), and 12 h light/dark cycles (06:00-18:00 h light, 18:00-06:00 dark). Briefly, Balb/c mice are sensitized on day -7 by a single application of 20 <math>\mu</math>L of 1.0% oxazolone in a mixture of acetone and olive oil (4:1) to the inner and outer surface of both ears. On day 0, the mouse ears are challenged with 20 <math>\mu</math>L of 0.1% oxazolone at 2-day intervals for 4 weeks post-sensitization. The mice are treated with the indicated concentrations of Eupatilin (1.5% or 3.0%) twice a day for 4 weeks. The control group is treated with vehicle alone (acetone and olive oil [4:1]). After 3 weeks, the mice are sacrificed and samples are collected. Ears are stored at -80°C for RNA isolation and analysis or immediately fixed in 4% formalin for histological analysis<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## CUSTOMER VALIDATION

- Acta Pharm Sin B. 2021 Jan;11(1):143-155.
- Life Sci. 2020 Jul 15;253:117745.
- Int J Mol Med. 2021 Feb;47(2):511-522.
- J Inflamm Res. 2023 Mar 10.
- Animals (Basel). 2024 Jan 30;14(3):449.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Jung Y, et al. Eupatilin, an activator of PPAR $\alpha$ , inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice. *Biochem Biophys Res Commun*. 2018 Feb 5;496(2):508-514.
- [2]. Jung Y, et al. Eupatilin with PPAR $\alpha$  agonistic effects inhibits TNF $\alpha$ -induced MMP signaling in HaCaT cells. *Biochem Biophys Res Commun*. 2017 Nov 4;493(1):220-226.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA